Literature DB >> 9353692

Pharmacokinetic-pharmacodynamic modeling of doxacurium: effect of input rate.

Y Zhu1, G Audibert, F Donati, F Varin.   

Abstract

One of the basic assumptions in pharmacokinetic-pharmacodynamic modeling (PK-PD) is that drug equilibration rate constant between plasma concentration and effect (Ke0) is not changed by input rate. To test this assumption in a clinical setting, a 25 micrograms/kg i.v. dose of doxacurium was administered either by bolus injection or 10-min infusion to 15 anesthetized patients. Neuro-muscular function was monitored using train-of-four stimulation of the ulnar nerve. For the short infusion dose, arterial concentrations were measured at I-min intervals during infusion and at frequent intervals thereafter. Following the iv bolus dose, the early PK profile of doxacurium was investigated by measuring doxacurium arterial concentrations every 10 sec during the first 2 min and at frequent intervals thereafter. PK-PD modeling was performed using nonparametric approach with and without including a finite receptor concentration (Rtot) in the effect compartment. Kinetic parameters were unchanged. For the bolus and the infusion, Ke0 values were 0.053 +/- 0.006 and 0.056 +/- 0.009 min-1, respectively. Using the Rtot model, corresponding Ke0 values were 0.148 +/- 0.016 and 0.150 +/- 0.024, respectively. The relatively faster Ke0 obtained with the Rtot model is compatible with the high potency of doxacurium. Our results show that PK-PD parameters derived with either a bolus or an infusion mode of administration are equally reliable.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9353692     DOI: 10.1023/a:1025715626164

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  20 in total

Review 1.  The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part II).

Authors:  W L Chiou
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

2.  A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs.

Authors:  F Donati; C Meistelman
Journal:  J Pharmacokinet Biopharm       Date:  1991-10

3.  Interaction between nondepolarizing neuromuscular blocking agents and inhalational anesthetics.

Authors:  J Swen; O M Rashkovsky; J M Ket; H W Koot; J Hermans; S Agoston
Journal:  Anesth Analg       Date:  1989-12       Impact factor: 5.108

4.  Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models.

Authors:  J D Unadkat; F Bartha; L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1986-07       Impact factor: 6.875

Review 5.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

6.  Pharmacokinetics of mivacurium isomers and their metabolites in healthy volunteers after intravenous bolus administration.

Authors:  M Lacroix; F Donati; F Varin
Journal:  Anesthesiology       Date:  1997-02       Impact factor: 7.892

7.  Pharmacokinetics and pharmacodynamics of atracurium obtained with arterial and venous blood samples.

Authors:  F Donati; F Varin; J Ducharme; S S Gill; Y Théorêt; D R Bevan
Journal:  Clin Pharmacol Ther       Date:  1991-05       Impact factor: 6.875

8.  Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia.

Authors:  D L Dresner; S J Basta; H H Ali; A F Schwartz; P B Embree; W A Wargin; A A Lai; K A Brady; J J Savarese
Journal:  Anesth Analg       Date:  1990-11       Impact factor: 5.108

9.  Vecuronium-induced neuromuscular blockade during enflurane, isoflurane, and halothane anesthesia in humans.

Authors:  S M Rupp; R D Miller; P J Gencarelli
Journal:  Anesthesiology       Date:  1984-02       Impact factor: 7.892

10.  Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia.

Authors:  C A Shanks; M J Avram; R J Fragen; D A O'Hara
Journal:  Clin Pharmacol Ther       Date:  1987-10       Impact factor: 6.875

View more
  3 in total

1.  Do plasma concentrations obtained from early arterial blood sampling improve pharmacokinetic/pharmacodynamic modeling?

Authors:  T M Beaufort; J H Proost; K Kuizenga; M C Houwertjes; U W Kleef; J M Wierda
Journal:  J Pharmacokinet Biopharm       Date:  1999-04

2.  Peripheral link model as an alternative for pharmacokinetic-pharmacodynamic modeling of drugs having a very short elimination half-life.

Authors:  J Laurin; F Donati; F Nekka; F Varin
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-02       Impact factor: 2.745

3.  Assuming peripheral elimination: its impact on the estimation of pharmacokinetic parameters of muscle relaxants.

Authors:  J Laurin; F Nekka; F Donati; F Varin
Journal:  J Pharmacokinet Biopharm       Date:  1999-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.